



Article

# Elevated Levels of Circulating lncRNAs LIPCAR and MALAT1 Predict an Unfavorable Outcome in Acute Coronary Syndrome Patients

Teodora Barbalata <sup>1,†</sup>, Loredan S. Niculescu <sup>1,†</sup> , Camelia S. Stancu <sup>1</sup>, Florence Pinet <sup>2</sup>  and Anca V. Sima <sup>1,\*</sup>

<sup>1</sup> Lipidomics Department, Institute of Cellular Biology and Pathology “Nicolae Simionescu” of the Romanian Academy, 8 Bogdan Petriceicu Hasdeu Street, 050568 Bucharest, Romania; teodora.barbalata@icbp.ro (T.B.); loredan.niculescu@icbp.ro (L.S.N.); camelia.stancu@icbp.ro (C.S.S.)

<sup>2</sup> U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillessement, Institut Pasteur de Lille, Université de Lille, INSERM, CHU Lille, F-59000 Lille, France; florence.pinet@pasteur-lille.fr

\* Correspondence: anca.sima@icbp.ro

† These authors contributed equally to this work.

**Abstract:** Coronary artery disease (CAD) is a leading cause of mortality worldwide. In this study, we aimed to assess the potential of plasma long non-coding RNAs (lncRNAs) LIPCAR and MALAT1 and microRNAs (miRNAs) miR-142-3p and miR-155-5p to discriminate unstable CAD patients from stable ones. 23 stable angina (SA), 21 unstable angina (UA), and 50 ST-segment elevation myocardial infarction (STEMI) patients were enrolled; their plasma was collected. ncRNA plasma levels were evaluated using RT-qPCR. All measured ncRNA levels were significantly increased in UA patients' plasma compared to SA patients' plasma and in STEMI-with major adverse cardiovascular event (MACE) patients' plasma vs. STEMI-without MACE patients' plasma. ROC analysis showed that increased levels of LIPCAR and MALAT1 were associated with UA, and the prognostic model improved with the addition of miR-155-5p levels. The assessed lncRNAs discriminated between hyperglycemic (HG) and normoglycemic (NG) UA patients, and they were associated with MACE incidence in STEMI patients; this prediction was improved by the addition of miR-142-3p levels to the ROC multivariate model. We propose LIPCAR and MALAT1 as effective diagnostic markers for vulnerable CAD, their association with HG in UA patients, and as robust predictors for unfavorable evolution of STEMI patients.

**Keywords:** long non-coding RNA; LIPCAR; MALAT1; miR-155; miR-142; coronary syndrome; stable angina; unstable angina; STEMI; biomarker



**Citation:** Barbalata, T.; Niculescu, L.S.; Stancu, C.S.; Pinet, F.; Sima, A.V. Elevated Levels of Circulating lncRNAs LIPCAR and MALAT1 Predict an Unfavorable Outcome in Acute Coronary Syndrome Patients. *Int. J. Mol. Sci.* **2023**, *24*, 12076. <https://doi.org/10.3390/ijms241512076>

Academic Editors: Anastasios Lympieropoulos and Alexandre Mironov

Received: 14 June 2023  
Revised: 4 July 2023  
Accepted: 25 July 2023  
Published: 28 July 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Cardiovascular diseases (CVDs) are the leading cause of death worldwide, despite tireless efforts to find better diagnostic and prognostic tools. Understanding their underlying molecular mechanisms is key to the treatment of patients. Some of the most threatening CVDs are coronary artery diseases (CADs), which can be classified based on their severity as stable angina (SA), unstable angina (UA), and myocardial infarction (MI), the latter two being collectively known as acute coronary syndrome (ACS) [1]. Although there are some parameters currently used in the clinic to evaluate a patient's risk to develop MI, they have proven to be insufficient to discriminate CAD patients at risk [2]. There is an inherent need to find new and accurate prognostic biomarkers to predict CAD patients' evolution.

One of the emerging classes of promising molecules is long non-coding RNAs (lncRNAs), which are non-coding RNAs (ncRNAs) usually up to 200 nucleotides long. They were first observed in humans during cancer research [3], but they were later found to be implicated in CVD development as well [4]. Another class of ncRNAs that shows great

potential as diagnostic and prognostic biomarkers for CVD is microRNAs (miRNAs) [5], which are short ncRNA sequences usually 20–23 nucleotides long. Considerably more widely studied than lncRNAs, many miRNAs have been described in the literature as being involved in the regulation of many pathways relevant to CVD, such as those involved in cardiomyocyte contractility, hypertrophy, or fibrosis [6,7].

The regulation mechanisms of lncRNAs are fairly diverse and less studied. They are known to act by either direct interaction with chromatin, thus affecting its condensation state, or by binding to histones or transcription factors [8]. In the cytoplasm, lncRNAs have multiple mechanisms of action, such as inhibition of gene expression by binding to RNA-binding proteins specific for mRNA or even to mRNA molecules directly [9]. Alternatively, it has been reported that they can bind to and block miRNAs, forming so-called “miRNA-lncRNA sponges” that diminish the regulatory effects of miRNAs [10]. Another difference between lncRNAs and miRNAs is that the former are significantly less conserved than the latter, their expression being more tissue-specific and, therefore, they are less abundant in circulation [11].

Two lncRNAs that have been demonstrated to regulate different pathways relevant to CVD are uc022bqs.1 (long intergenic noncoding RNA predicting cardiac remodeling and survival of patients with heart failure—LIPCAR) and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1). LIPCAR is a relatively newly discovered mitochondrial lncRNA [12] that has been described to have a role in heart failure [13,14]. Although little is known about the pathways in which it is involved, there are some in vitro data suggesting that LIPCAR is implicated in endothelial cell and smooth muscle cell proliferation and migration [15,16]. MALAT1 is one of the most studied lncRNAs [17]. Although it was originally observed in cancer, it has been described in relation to CVD as well [18]. For example, it has been linked to lipid accumulation in macrophages treated with oxidized LDL (oxLDL) [19], suggesting a potential role in atherosclerotic plaque formation. MALAT1 was also found to be implicated in endothelial cell dysfunction, as demonstrated in HUVECs exposed to oxLDL [20].

Two microRNAs that are known to be involved in the regulation of CVD are miR-155-5p and miR-142-3p. miR-155-5p has been shown to promote atherosclerosis by affecting endothelial function [21], while elevated levels of miR-142-3p have been linked to major adverse cardiovascular events (MACEs) in ST-segment elevation myocardial infarction (STEMI) patients [22]. Both miR-155-5p and miR-142-3p have been reported to be regulated by MALAT1 in vitro via the “sponging” effect [23,24].

In the present study, we analyzed the distribution of LIPCAR, MALAT1, miR-155-5p, and miR-142-3p in the plasma of SA, UA, and STEMI patients in order to investigate their potential to discriminate ACS patients at risk. For SA and UA patients, the risk was considered to be hyperglycemia (HG), while for STEMI patients, MACE was considered to be the risk. We therefore correlated their circulating levels with HG and MACE, respectively.

## 2. Results

### 2.1. Plasma Biochemical Parameters of SA, UA, and STEMI Patients

Plasma lipid and oxidative stress parameters of SA, UA, and STEMI patients, with or without MACE, are presented in Table 1. Our results showed that patients with vulnerable CAD (UA and STEMI patients with MACE, respectively) had an aggravated biochemical plasma profile compared to SA and STEMI patients without MACE.

We found statistically significant increased levels of total cholesterol (TC) (by 21%,  $p = 0.011$ ), apolipoprotein E (ApoE) (by 33%,  $p = 0.024$ ), and C-reactive protein (CRP) (2-fold,  $p = 0.015$ ) in UA patients versus SA patients (Table 1). Of note, the observed CRP levels in ACS patients were elevated compared to the standard values. We further observed significantly increased levels of glucose (by 22%,  $p = 0.002$ ), CRP (by 61%,  $p = 0.008$ ), and LDH (by 47%,  $p = 0.001$ ) in the plasma of STEMI patients with MACE compared to STEMI patients without MACE (Table 1).

**Table 1.** Clinical parameters in the plasma of stable angina (SA), unstable angina (UA), and ST-segment elevation myocardial infarction (STEMI) patients.

Parameters	SA (n = 23)	UA (n = 21)	STEMI	
			no MACE (n = 38)	with MACE (n = 12)
Total cholesterol (mg/dL)	168 ± 7.52	204 ± 11.17 *	181 ± 7.85	182 ± 11.38
HDL-C (mg/dL)	43 ± 1.74	45.11 ± 3.25	25.83 ± 1.09 ***,###	24.62 ± 1.39 ***,###
LDL-C (mg/dL)	95 ± 6.72	114 ± 8.13	127 ± 7.65 *	127 ± 10.81 *
Triglycerides (mg/dL)	166 ± 15.23	164 ± 17.73	140 ± 6.98	155 ± 17.13
ApoA-I (mg/dL)	151 ± 9.11	146 ± 8.10	98 ± 5.99 ***,###	92 ± 9.17 ***,###
ApoE (mg/dL)	2.16 ± 0.15	2.89 ± 0.28 *	2.32 ± 0.15 #	2.31 ± 0.21
Glucose (mg/dL)	122 ± 6.23	135 ± 8.49	100 ± 3.05 ***,###	122 ± 7.67 \$\$
PON1 protein (µg/mL)	4.40 ± 0.39	3.65 ± 0.33	2.76 ± 0.12 ***,##	2.58 ± 0.20 **,#
PON1 activity (U/L)	446 ± 61.61	364 ± 61.47	380 ± 44.92	290 ± 68.53
MPO protein (µg/mL)	36.7 ± 2.84	42.7 ± 4.22	56.5 ± 6.16 *	67.1 ± 12.52 **,#
CRP (µg/mL)	17.0 ± 2.69	35.5 ± 6.99 *	22.6 ± 2.29 #	36.6 ± 4.40 is **,\$\$
LDH (U/L)	1547 ± 94.16	1990 ± 213.6	4454 ± 259.08 ***,###	6589 ± 700.15 is ***,###,\$\$


Data are given as mean ± SEM. Variations between the parameters of “SA”, “UA”, “STEMI-no MACE”, and “STEMI-with MACE” groups were analyzed using independent Student’s *t*-tests and considered statistically significant when the *p*-value was below 0.05 (\* vs. SA; # vs. UA), below 0.01 (\*\* vs. SA; ## vs. UA; \$\$ vs. STEMI-no MACE), or below 0.001 (\*\*\*) vs. SA; ### vs. UA). HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA-I, apolipoprotein A-I; ApoE, apolipoprotein E; PON1, paraoxonase 1; MPO, myeloperoxidase; CRP, C-reactive protein; LDH, lactate dehydrogenase; SEM, standard error of the mean.

It is known that hyperglycemia is a risk factor for CVD in SA ( $n = 7/23$ ) and UA ( $n = 10/21$ ) patients, suggesting an aggravated biochemical plasma profile compared to normoglycemic patients. We found that levels of ApoA-I (by 30%,  $p = 0.028$ ) and the enzymatic activity of PON1 (by 58%,  $p = 0.002$ ) were significantly decreased in the plasma of SA-HG patients compared to SA-normoglycemic (SA-NG) patients. We also found that PON1 activity was decreased (by 58%,  $p = 0.042$ ) while MPO protein levels were increased (by 55%,  $p = 0.044$ ) in the plasma of UA-HG patients compared to UA-NG patients (Table S1, Supplementary Material).


Interestingly, we found biochemical parameters that could differentiate between SA and UA hyperglycemic patients, with significantly increased apolipoprotein A-I (ApoA-I) (by 47%,  $p = 0.026$ ) levels and significantly decreased paraoxonase 1 (PON1) protein (by 38%,  $p = 0.008$ ) levels in the plasma of UA-HG patients compared to SA-HG patients (by 47%,  $p = 0.026$  for ApoA-I and by 61%,  $p = 0.008$  for PON1 protein), while ApoE levels were higher between the same groups (by 67%,  $p = 0.036$ ) (Table S1).

## 2.2. Distribution of ncRNAs in the Plasma of SA, UA, and STEMI Patients

The distribution of ncRNAs in the plasma of SA, UA, and STEMI patients is presented in Figure 1. LIPCAR levels were significantly higher in the plasma of vulnerable CAD patients: UA (by 24%,  $p = 6.07 \times 10^{-4}$ ) and STEMI-with MACE (by 32%,  $p = 3.46 \times 10^{-4}$ ) compared to SA patients. Levels of LIPCAR were increased in the plasma of STEMI-with MACE patients compared to STEMI-no MACE patients (by 22%,  $p = 0.0025$ ) (Figure 1a). Interestingly, LIPCAR levels were significantly increased in the plasma of UA-HG patients compared to SA-HG patients (by 18%,  $p = 0.0061$ ) (Figure 2a).



**Figure 1.** Levels of ncRNAs in the plasma of SA and UA patients with NG or HG and STEMI patients with or without MACE: LIPCAR (a), MALAT1 (b), miR-155-5p (c), miR-142-3p (d). Data are illustrated as boxplots with Tukey whiskers and median line. \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ .



**Figure 2.** Levels of ncRNAs in the plasma of hyperglycemic (HG) SA and UA patients compared to normoglycemic (NG) patients: LIPCAR (a), MALAT1 (b), miR-155-5p (c), miR-142-3p (d). Data are illustrated as boxplots with Tukey whiskers and median line. \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ .

MALAT1 levels were significantly increased in the plasma of UA (by 11%,  $p = 3.11 \times 10^{-4}$ ), STEMI-no MACE (by 6%,  $p = 0.0079$ ), and STEMI-with MACE (by 21%,  $p = 2.46 \times 10^{-5}$ ) patients compared to the SA group, and they were also increased in STEMI-with MACE patients compared to both UA (by 9%,  $p = 0.04$ ) and STEMI-no MACE (by 13%,  $p = 0.0013$ ) patients (Figure 1b). MALAT1 levels in the plasma of UA-NG patients were increased compared to SA-NG (by 50%,  $p = 4.35 \times 10^{-7}$ ) and SA-HG (by 36%,  $p = 3.21 \times 10^{-5}$ ) patients. Plasma levels of MALAT1 in UA-HG patients were significantly increased compared to SA-NG (by 60%,  $p = 1.26 \times 10^{-7}$ ) and SA-HG (by 46%,  $p = 9.81 \times 10^{-6}$ ) patients (Figure 2b).

Levels of miR-155-5p were significantly increased in the plasma of UA (by 7%,  $p = 0.004$ ), STEMI-no MACE (by 32%,  $p = 1.24 \times 10^{-12}$ ), and STEMI-with MACE (by 46%,  $p = 7.53 \times 10^{-11}$ ) patients compared to SA patients. Additionally, miR-155-5p levels were increased in the plasma of STEMI-no MACE (by 22%,  $p = 3.90 \times 10^{-9}$ ) and STEMI-with MACE (by 35%,  $p = 3.09 \times 10^{-9}$ ) patients compared to UA patients, as well as in STEMI-with MACE patients vs. STEMI-no MACE patients (by 11%,  $p = 0.0065$ ) (Figure 1c). Higher levels were detected in the plasma of UA-NG patients vs. SA-NG patients (by 7%,  $p = 0.047$ ), as well as in the plasma of UA-HG patients compared to SA-HG (by 10%,  $p = 0.007$ ) and SA-NG (by 12%,  $p = 0.0019$ ) patients (Figure 2c). Additionally, miR-142-3p


levels were increased in the plasma of SA-HG patients (by 13%,  $p = 0.009$ ) compared to UA-NG patients, while UA-HG patients had higher levels than SA-NG patients (by 16%,  $p = 3.15 \times 10^{-4}$ ).

Levels of miR-142-3p were significantly increased in UA (by 8%,  $p = 0.0036$ ) and STEMI-with MACE patients (by 9%,  $p = 0.008$ ) compared to SA patients, and also in the STEMI-with MACE group compared to the STEMI-no MACE group (by 7%,  $p = 0.0055$ ), but they were decreased in the STEMI-no MACE group compared to UA patients (by 6%,  $p = 0.0036$ ) (Figure 1d). Interestingly, miR-142-3p levels were significantly increased in HG patients compared to NG patients with SA (by 17%,  $p = 4.86 \times 10^{-4}$ ) and UA (by 12%,  $p = 0.0081$ ) (Figure 2d).

In conclusion, we found statistically significant differences in LIPCAR, MALAT1, and miR-142-3p levels between NG and HG patients in the UA group and only in miR-142-3p levels in SA patients (Figure 2).

### 2.3. Correlations between lncRNAs, miRNAs, and Main Biochemical Parameters in Plasma of CAD Patients

Correlations between plasma levels of selected lncRNAs, miRNAs, and main plasma parameters in CAD patients were estimated separately for the SA and UA groups using Pearson's analysis. Significant correlations were observed for plasma lncRNA LIPCAR levels with lncRNA MALAT1 ( $R = 0.604$ ,  $p = 0.029$ ) and miR-142-3p ( $R = 0.638$ ,  $p = 0.026$ ) levels in UA patients, and with miR-142-3p ( $R = 0.596$ ,  $p = 0.019$ ) and miR-155-5p ( $R = -0.670$ ,  $p = 0.009$ ) levels in SA patients. Plasma lncRNA MALAT1 levels were significantly correlated with plasma miR-142-3p ( $R = 0.608$ ,  $p = 0.042$ ) levels only in UA patients (Figure 3 and Table S2, Supplementary Material).



**Figure 3.** Correlation plots for stable (SA) (a) and unstable angina (UA) (b) patients. Bivariate Spearman's nonparametric correlations between plasma lncRNA (LIPCAR, MALAT1) and miRNA (miR-142-3p, miR-155-5p) levels with age, biochemical parameters, enzymatic activity, and inflammatory stress-related parameters. Data were illustrated as correlation plot graphs using R-studio software (version 2022.12.0+353).

When analyzing the associations of measured lncRNA levels with lipid metabolism-associated parameters, we observed significant and positive correlations between LIPCAR levels and total cholesterol ( $R = 0.633$ ,  $p = 0.008$ ) or ApoA-I ( $R = -0.602$ ,  $p = 0.014$ ) levels in the SA group. No significant correlations were found between plasma levels of MALAT1 and lipid metabolism-related parameters in SA or UA patients. In the plasma of SA patients, significant correlations were observed between miR-142-3p and ApoA-I levels ( $R = -0.569$ ,  $p = 0.022$ ), while miR-155-5p levels were positively correlated with ApoE levels ( $R = 0.516$ ,  $p = 0.034$ ) (Figure 3 and Table S3, Supplementary Material).


We also analyzed the correlations between lncRNA and miRNA levels with parameters associated with oxidative stress. Plasma LIPCAR levels were positively correlated with



PON1 protein levels in SA patients ( $R = 0.645$ ,  $p = 0.009$ ), while a strong positive correlation was observed with MPO protein levels ( $R = 0.715$ ,  $p = 6.01 \times 10^{-3}$ ) in UA patients. Plasma MALAT1 levels showed a negative correlation with PON1 activity ( $R = -0.686$ ,  $p = 0.016$ ) in UA patients. Similarly, miR-142-3p levels were negatively correlated with PON1 activity in the plasma of both SA ( $R = -0.812$ ,  $p = 0.014$ ) and UA ( $R = -0.765$ ,  $p = 0.031$ ) patients (Figure 3 and Table S4, Supplementary Material).

We further analyzed the potential associations of lncRNA and miRNA levels with cardiac parameters, and we observed that MALAT1 levels had a strong positive correlation with LDH levels ( $R = 0.861$ ,  $p = 0.010$ ) only in UA patients (Figure 3 and Table S4, Supplementary Material). No significant correlations were observed between plasma levels of lncRNAs and miRNAs with an inflammatory stress-related parameter (CRP) either in SA or UA patients (Figure 3 and Table S4, Supplementary Material).

The most interesting associations were observed between the analyzed lncRNAs and miRNAs with glucose levels in the plasma of SA and UA patients, illustrated as scatter plots in Figure 4 and detailed in Table S3. LIPCAR and MALAT1 levels were positively correlated with glucose levels only in UA patients ( $R = 0.561$ ,  $p = 0.030$ , and  $R = 0.621$ ,  $p = 0.013$ , respectively) (Figure 4a,b and Table S3, Supplementary Material). Plasma miR-142-3p levels displayed strong correlations with glucose levels both in SA ( $R = 0.717$ ,  $p = 2.68 \times 10^{-3}$ ) and UA ( $R = 0.586$ ,  $p = 0.022$ ) patients. In contrast, no significant correlations were found between plasma miR-155-5p and glucose levels (Figure 4c,d and Table S3, Supplementary Material).




**Figure 4.** Scatter plots and linear regression curves. The associations between plasma levels of glucose and ncRNAs: LIPCAR (a), MALAT1 (b), miR-155-5p (c), and miR-142-3p (d) in stable (SA, blue dots and lines) and unstable angina (UA, red dots and lines) patients.

#### 2.4. Correlations between lncRNAs, miRNAs, and Main Parameters in Plasma of STEMI Patients

Similar correlations between lncRNAs and miRNAs with main plasma parameters were investigated in STEMI patients (Figure 5, and detailed in Table S5, Supplementary Material). We observed that plasma LIPCAR levels were positively correlated with MALAT1 ( $R = 0.405$ ,

$p = 0.014$ ), miR-142-3p ( $R = 0.528, p = 6.58 \times 10^{-4}$ ), and miR-155-5p ( $R = 0.826, p = 1.70 \times 10^{-10}$ ) levels in STEMI patients. Significant positive correlations were also observed between plasma miR-155-5p levels with MALAT1 ( $R = 0.424, p = 0.010$ ) and miR-142-3p ( $R = 0.628, p = 2.16 \times 10^{-7}$ ) levels (Figure 5 and Table S5, Supplementary Material).



**Figure 5.** Correlation plot for ST-segment elevation myocardial infarction (STEMI) patients. Bivariate Spearman's nonparametric correlations between serum lncRNA (LIPCAR, MALAT1) and miRNA (miR-142-3p, miR-155-5p) levels with age, biochemical parameters, enzymatic activity, and inflammatory stress-related parameter. Data were illustrated as a correlation plot graph using R-studio software (version 2022.12.0+353).


We analyzed the correlations between lncRNA and miRNA levels with lipid metabolism-associated parameters in the plasma of STEMI patients, and we observed moderate significant correlations between LIPCAR and ApoE ( $R = -0.356, p = 0.028$ ), MALAT1 and ApoA-I ( $R = -0.384, p = 0.025$ ), and miR-155-5p and ApoE ( $R = -0.362, p = 6.15 \times 10^{-3}$ ) levels. Only MALAT1 levels correlated with glucose levels ( $R = 0.468, p = 8.97 \times 10^{-3}$ ) in the plasma of STEMI patients (Figure 5 and Table S6, Supplementary Material).

Correlations between parameters associated with oxidative stress in the plasma of STEMI patients were determined, with LIPCAR and miR-155-5p levels associated with MPO protein levels ( $R = 0.373, p = 0.025$ , and  $R = 0.380, p = 4.63 \times 10^{-3}$ , respectively). We further analyzed the associations with cardiac parameters in the plasma of STEMI patients, and we observed that only miR-142-3p levels showed a significant correlation with CRP levels ( $R = 0.316, p = 0.024$ ) (Figure 5 and Table S7, Supplementary Material).

### 2.5. Plasma lncRNA and miRNA Levels as Predictors for Vulnerable CAD Patients: The Impact of Hyperglycemia

We estimated the prediction power of the analyzed ncRNAs for the prediction of vulnerability evolution in ACS patients using receiver operating characteristic (ROC) analysis, adjusted for age and gender. The reference was the SA group and the risk group was the UA group. Except for miR-142-3p, each of analyzed ncRNAs could be used as individual predictors for vulnerable CAD (UA diagnosis) in ACS patients in univariate ROC analysis, whereas miR-155-5p levels were shown to be the strongest independent

predictor (highest AUC = 0.812,  $p = 3.55 \times 10^{-3}$ ), followed by MALAT1 (AUC = 0.773,  $p = 3.27 \times 10^{-3}$ ) and LIPCAR (AUC = 0.737,  $p = 0.022$ ) levels (Table S8 and Figure 6).




**Figure 6.** Receiver operator characteristic (ROC) curves. The discriminating potential of univariate and multivariate models for diagnosis of acute coronary syndrome—unstable angina (UA) versus stable angina (SA)—in patients using plasma levels of lncRNA LIPCAR, lncRNA MALAT1, miR-155-5p, or miR-142-3p (a,b), and multivariate models (c) using plasma levels of two lncRNAs or two lncRNAs plus miR-155-5p or miR-142-3p.

The multivariate ROC analysis indicated that the combination of the two lncRNAs, LIPCAR and MALAT1, could strongly predict vulnerable CAD (multivariate model 1, AUC = 0.870,  $p = 7.34 \times 10^{-4}$ ) (Table S8 and Figure 6). The addition of miR-155-5p levels to the multivariate model 1 significantly improved the prediction of vulnerable CAD (UA diagnosis) (multivariate model 2, AUC = 0.938,  $p = 4.08 \times 10^{-4}$ ), while the addition of miR-142-3p levels failed to improve the model but the prediction still remained statistically significant (multivariate model 3, AUC = 0.836,  $p = 5.92 \times 10^{-3}$ ) (Table S8 and Figure 6). According to these data, the minimal model for discriminating vulnerable CAD was based on plasma LIPCAR, MALAT1, and miR-155-5p levels.

Using the same statistical approach of ROC analysis, we evaluated the discriminating potential of the selected lncRNA and miRNA levels for vulnerable CAD diagnosis (UA-risk group versus SA-reference group) in the two subgroups of CAD patients defined by the presence of hyperglycemia (Figure 7a–d and Table 2). We obtained significant and powerful predictions of vulnerable CAD, mostly in HG patients, with the highest AUC achieved using MALAT1 levels (AUC = 0.952,  $p = 6.66 \times 10^{-15}$ ), followed by miR-155-5p (AUC = 0.905,  $p = 2.32 \times 10^{-6}$ ) and LIPCAR (AUC = 0.900,  $p = 7079 \times 10^{-5}$ ) levels. In contrast, miR-142-3p levels failed to discriminate vulnerable CAD in the HG group as well



as in NG patients (Figure 7a–d and Table 2). Of note, miR-155-5p levels had a good AUC value in the ROC analysis for vulnerable CAD in NG patients but failed to reach statistical significance (AUC = 0.717,  $p = 0.121$ ).



**Figure 7.** Receiver operator characteristic (ROC) curves. Univariate analysis for the discriminating potential of vulnerable coronary artery disease (CAD)—unstable angina (UA) versus stable angina (SA)—using plasma levels of LIPCAR (a), MALAT1 (b), miR-142-3p (c), and miR-155-5p (d) in hyperglycemic (HG) and normoglycemic (NG) CAD patients.

Further, we analyzed independent-group AUC differences in the ROC analysis between the NG and HG groups of CAD patients. We found that the discriminating potential for vulnerable CAD using plasma LIPCAR and MALAT1 levels was significantly higher in HG patients than in the NG group ( $z$  value =  $-2.272$ ,  $p = 0.023$ , and  $z = -2.588$ ,  $p = 0.010$ , respectively) (Table 3).

**Table 2.** Area under the receiver operator characteristic (ROC) curves of univariate analysis for the discriminating potential of acute coronary syndrome—unstable angina (UA) versus stable angina (SA)—using plasma levels of lncRNA LIPCAR, lncRNA MALAT1, miR-142-3p, and miR-155-5p in hyperglycemic (HG) and normoglycemic (NG) CAD patients.

Area Under the ROC Curve—UA vs. SA Analysis						
Test Result Variable(s)	Glycemia	Area	Std. Error <sup>a</sup>	<i>p</i> -Value <sup>b</sup>	Asymptotic 95% Confidence Interval	
					Lower Bound	Upper Bound
LIPCAR	Normoglycemic group	0.486	0.152	0.925	0.188	0.783
	Hyperglycemic group	0.900	0.101	$7.79 \times 10^{-5}$	0.702	1.098
MALAT1	Normoglycemic group	0.587	0.129	0.502	0.334	0.839
	Hyperglycemic group	0.952	0.058	$6.66 \times 10^{-15}$	0.839	1.066
miR-142-3p	Normoglycemic group	0.622	0.137	0.372	0.354	0.891
	Hyperglycemic group	0.367	0.176	0.448	0.022	0.711
miR-155-5p	Normoglycemic group	0.717	0.121	0.074	0.479	0.954
	Hyperglycemic group	0.905	0.086	$2.32 \times 10^{-6}$	0.737	1.073

<sup>a</sup> Under the nonparametric assumption; <sup>b</sup> Null hypothesis: true area = 0.5.

**Table 3.** Comparative analysis of area under the receiver operator characteristic (ROC) curves between univariate analysis in hyperglycemic (HG) and normoglycemic (NG) patients for the discriminating potential of acute coronary syndrome—unstable angina (UA) versus stable angina (SA)—using plasma levels of lncRNA LIPCAR, lncRNA MALAT1, miR-142-3p, and miR-155-5p.


Independent-Group Area Difference Under the ROC Curve						
Test Result Variable(s)	Asymptotic		AUC Difference	Std. Error Difference <sup>b</sup>	Asymptotic 95% Confidence Interval	
	<i>z</i>	<i>p</i> -Value <sup>a</sup>			Lower Bound	Upper Bound
LIPCAR	−2.272	0.023	−0.414	0.182	−0.772	−0.057
MALAT1	−2.588	0.010	−0.366	0.141	−0.643	−0.089
miR-142-3p	1.147	0.251	0.256	0.223	−0.181	0.692
miR-155-5p	−1.268	0.205	−0.188	0.148	−0.479	0.103

<sup>a</sup> Null hypothesis: true area difference = 0; <sup>b</sup> Under the nonparametric assumption.

## 2.6. Plasma lncRNA and miRNA Levels as Predictors for MACE Occurrence in STEMI Patients

When analyzing the univariate ROC prediction for subsequent MACE in STEMI patients, we found that the selected lncRNAs and miRNAs had significant individual prognostic value. Accordingly, the highest AUC for MACE occurrence in STEMI patients was calculated for LIPCAR levels (AUC = 0.815,  $p = 0.004$ ), followed by MALAT1 (AUC = 0.792,  $p = 0.007$ ), miR-142-3p (AUC = 0.815,  $p = 0.004$ ), and miR-155-5p (AUC = 0.815,  $p = 0.004$ ) levels (Figure 8a and Table 4).

We then combined these ncRNAs in a multivariate ROC analysis and we proved that the combination of plasma levels of LIPCAR and MALAT1 could significantly predict future MACE in STEMI patients (AUC = 0.842,  $p = 0.002$ ) (multivariate model 1 in Figure 8b and Table 4). The individual addition of miR-155-5p (multivariate model 2) and miR-142-3p levels (multivariate model 3) to model 1 significantly improved the prediction of new MACE (AUC = 0.896,  $p = 2.75 \times 10^{-4}$ , and AUC = 0.919,  $p = 1.18 \times 10^{-4}$ , respectively). Of note, the model with miR-142-5p levels had a higher AUC than that with miR-155-5p levels (Figure 8b and Table 4). The multivariate model using all analyzed ncRNAs did not further improve the prediction. Similar to the vulnerable CAD discrimination model, the minimal model predicting subsequent MACE in STEMI patients was based on LIPCAR and MALAT1 levels, with an improvement when using miR-142-3p levels.



**Figure 8.** Receiver operator characteristic (ROC) curve. The predictive potential of univariate (a) and multivariate (b) models for major adverse cardiovascular events (MACEs) during follow-up in ST-elevation myocardial infarction (STEMI) patients using plasma levels of lncRNA LIPCAR, lncRNA MALAT1, miR-155-5p, or miR-142-3p (a) and combination models (b) using plasma levels of two lncRNAs (model 1) plus miR-155-5p (model 2), miR-142-3p (model 3), or the two miRNAs (model 4).

**Table 4.** Receiver operator characteristic (ROC) analysis for predictive potentials of individual and combined models for major adverse cardiovascular events (MACEs) during follow-up in ST-elevation myocardial infarction (STEMI) patients, using plasma lncRNA LIPCAR, lncRNA MALAT1, miR-155-5p, and miR-142-3p levels.

Test Result Variable(s) *	Area Under the Curve			Asymptotic 95% Confidence Interval	
	Area	Standard Error <sup>a</sup>	<i>p</i> -Value <sup>b</sup>	Lower Bound	Upper Bound
<b>Univariate models</b>					
LIPCAR	0.815	0.074	0.004	0.670	0.961
MALAT1	0.792	0.078	0.007	0.640	0.945
miR-155-5p	0.769	0.098	0.013	0.577	0.962
miR-142-3p	0.756	0.103	0.019	0.554	0.958
<b>Multivariate models</b>					
Multivariate model 1 (LIPCAR and MALAT1)	0.842	0.068	0.002	0.710	0.975
Multivariate model 2 (LIPCAR, MALAT1, and miR-155-5p)	0.896	0.064	$2.75 \times 10^{-4}$	0.771	1.000
Multivariate model 3 (LIPCAR, MALAT1, and miR-142-3p)	0.919	0.045	$1.18 \times 10^{-4}$	0.832	1.000
Multivariate model 4 (lncRNAs LIPCAR and MALAT1, plus miR-142-3p and miR-155-5p)	0.919	0.045	$1.18 \times 10^{-4}$	0.832	1.000

\* All adjusted for age and gender (male as risk). <sup>a</sup> Under the nonparametric assumption. <sup>b</sup> Null hypothesis: true area = 0.5.

### 3. Discussion

Understanding the underlying molecular mechanisms involved in CVD is key to the successful treatment of patients. In the present study, we set out to investigate the potential of circulating lncRNAs LIPCAR and MALAT1 to discriminate ACS patients at risk. Furthermore, we evaluated the additional contribution of miR-155-5p and miR-142-3p to the prognostic properties of the lncRNAs of interest.

In this study, we report that in SA and UA patients: (i) LIPCAR, MALAT1, miR-142-3p, and miR-155-5p levels are significantly elevated in the plasma of vulnerable CAD (UA) compared to SA patients; (ii) LIPCAR, MALAT1, and miR-142-3p levels are significantly increased in the plasma of UA-HG patients compared to NG ones, while miR-142-3p presents at higher levels in the plasma of SA-HG patients vs. SA-NG patients; (iii) LIPCAR, MALAT1, and miR-142-3p levels are positively correlated with glucose levels and oxidative stress parameters in UA patient plasma; (iv) LIPCAR, MALAT1, and miR-155-5p levels could be used as individual predictors for vulnerable CAD (UA) in univariate ROC analysis only for HG patients; (v) the minimal multivariate ROC model discriminating between vulnerable and stable CAD is based on plasma LIPCAR and MALAT1 levels, with minimal improvement by miR-155-5p addition.

The data obtained in STEMI patients show that: (i) plasma levels of LIPCAR, MALAT1, miR-155-5p, and miR-142-3p are significantly higher in STEMI patients with MACE than in those without MACE; (ii) MALAT1 levels correlate with glucose and LDH levels, while LIPCAR levels correlate with oxidative stress parameters; (iii) LIPCAR, MALAT1, miR-142-3p, and miR-155-5p levels have significant individual prognostic value in univariate ROC analysis for subsequent MACE in STEMI patients; (iv) the minimal multivariate ROC model predicting subsequent MACE in STEMI patients is based on LIPCAR and MALAT1 levels, with some improvement by adding miR-142-3p levels. The novelty of our study is that the combined use of two lncRNAs, LIPCAR and MALAT1, measured in the plasma of ACS patients, may discriminate vulnerable CAD from SA, correlate with hyperglycemia in UA patients, and predict unfavorable evolution (MACE) of STEMI patients.

The most interesting and new data obtained in the present study are about LIPCAR, since it is still a relatively newly discovered mitochondrial lncRNA [12] with few published data proving its functional role. We show here that LIPCAR levels are increased in vulnerable CAD patients compared to SA patients and are strongly associated with hyperglycemia in UA patients, being also predictive for MACE occurrence in STEMI patients. In good agreement with our data, other studies suggest that LIPCAR may have a role in predicting heart failure and cardiac remodeling [13] and in diagnosing UA [25]. Our data confirm the results of other studies performed in patients with well-controlled type 2 diabetes, showing that serum LIPCAR levels are associated with left ventricle diastolic function and remodeling [26]. Our results are in good agreement with the data of Li et al., who found that elevated LIPCAR levels may predict the severity and progression of CAD, being an independent predictor for MACE in STEMI patients [27]. The novelty of our study is that increased LIPCAR levels are associated with hyperglycemia in the plasma of UA patients.

However, little is known about the pathways in which the studied lncRNAs are involved. Published *in vitro* data suggested that LIPCAR is upregulated in exosomes derived from THP-1 monocytes incubated with oxidized LDL and that these exosomes could promote human umbilical endothelial cell (HUVEC) and smooth muscle cell (SMC) proliferation and, consequently, the progression of atherosclerosis [15]. Another published study showed that LIPCAR overexpression may promote vascular SMC proliferation, migration, and phenotypic switch [16]. We show here, for the first time, a strong statistical association between LIPCAR levels and hyperglycemia in UA patients and the strong potential of the LIPCAR-MALAT1 model for the prediction of unfavorable post-AMI evolution.

The other lncRNA analyzed in our study is MALAT1. We show that plasma levels of MALAT1 are associated with hyperglycemia in vulnerable CAD patients. We demonstrate that MALAT1 levels are independent predictors for subsequent MACE in STEMI patients, both in univariate and multivariate ROC models (combined with LIPCAR). In good agreement with our data, a recent study showed that increased MALAT1 levels in peripheral blood mononuclear cells (PBMCs) are related to elevated MACE incidence [28]. Vausort et al. demonstrated that MALAT1 levels in PBMCs are increased in AMI patients compared to healthy subjects and may help in the prediction of left ventricle dysfunction [29]. Our data are complementary to the results of Lv et al., who showed that serum MALAT1 levels

are predictive for subsequent MACE in CAD patients without AMI [30]. The novelty of our study is that MALAT1 levels can discriminate vulnerable CAD in HG patients and can predict MACE occurrence in STEMI patients using easier to perform lncRNA measurements in plasma and not PBMCs assessment.

The main mechanisms for post-transcriptional regulation by MALAT1 involve alternative splicing, but MALAT1 can also act as a competitive endogenous RNA (ceRNA) [31]. Interestingly, mRNAs can communicate with lncRNAs through miRNA response elements (MREs). MALAT1 uses the ceRNA regulatory system through negative regulation between MALAT1 and miRNAs [32]. Accordingly, it was demonstrated that MALAT1 physically interacts with some miRNAs, like the two miRNAs selected and analyzed in the present study, miR-155-5p and miR-142-3p. Wang et al. reported that MALAT1 can promote cell proliferation and migration in hypoxic cardiac stem cells, acting mechanistically by promoting MEF2A expression via sponging miR-155 [33]. Also, Chen et al. showed recently that MALAT1 can regulate intermittent hypoxia-induced injury of HUVECs via targeting miR-142-3p by direct interaction, as proven by luciferase-reporter assays [34]. In good agreement with these data, we found an expected positive correlation between MALAT1 and miR-142-3p levels in UA patients but not in SA patients. Furthermore, we found several statistically significant correlations between MALAT1 and LIPCAR levels, some biochemical parameters related to oxidative stress, such as PON1 activity and MPO protein levels, and LDH levels only in the UA group, which further supports the diagnostic potential of lncRNAs for vulnerable CAD. Additionally, the two minimal ROC analysis statistical models using LIPCAR and MALAT1 levels to discriminate vulnerable CAD (UA vs. SA patients) and to predict MACE in STEMI patients could be moderately improved by adding miR-155-5p and miR-142-3p levels, respectively. Since we found a possible association between MALAT1 levels and miR-155-5p or miR-142-3p levels in plasma, we cannot exclude an interaction between them in cardiac or vascular cells that may regulate their plasma levels. Based on these data, we hypothesize that the association of MALAT1 with selected miRNAs may happen only in acute cardiac events.

One possible limitation of our study is the relatively small number of CAD and STEMI patients analyzed. Although the number of recruited CAD and STEMI patients from the previous studies was rather small, the employed statistical analyses and ROC models, as well as the distribution of lncRNAs and miRNAs levels, showed statistically significant results. Another potential drawback is that despite the well-designed measurement techniques used, there are no standardized methods to quantify the absolute levels of blood cell-free circulating (plasma compartment) lncRNAs and miRNAs, making the comparison between data obtained in different laboratories difficult.

Taking all these data together, we propose LIPCAR and MALAT1 as potential prognostic markers of vulnerability in CAD patients and as robust predictors for unfavorable evolution (MACE) of STEMI patients. These lncRNAs can be easily quantified in plasma using the fast and reliable TaqMan-based PCR method, which is available in most clinical hospitals. However, a deeper understanding of lncRNA functions and their interaction networks is needed. This would lead to the development of lncRNAs as promising therapeutic targets and as validated diagnostic or prognostic biomarkers for vulnerable CAD.

#### 4. Materials and Methods

##### 4.1. Study Design: SA, UA, and STEMI Patients

For the present study, we used plasma samples available in our biobank from previous studies [22,35]. A total of 94 patients were enrolled as follows: 23 SA patients (7 females and 16 males, aged between 44 and 79 years old), 21 UA patients (14 females and 7 males, aged between 42 and 70 years old), and 50 STEMI patients (all males, aged between 33 and 68 years old). SA and UA patients were enrolled at the Cardiology Clinic, Elias Emergency University Hospital, Bucharest, while STEMI patients were from the Floreasca Emergency Hospital, Bucharest, Romania.



Inclusion of patients in the SA, UA, or STEMI groups was performed according to the clinical practice guidelines of the European Society of Cardiology (ESC) [1,36] by clinical assessment, cardiac biomarkers levels, electrocardiography, and echocardiography. Patients presenting previous myocardial infarction, cardiac surgery, active malignancy, auto-immune diseases, severe hepatic/respiratory/renal failure, recent surgery, or trauma were excluded from the study.

STEMI patients were monitored for the occurrence of post-STEMI MACE. We defined MACE according to the guidelines described by the ESC [36] as recurrent ischemia/reinfarction requiring hospital admission and repeated percutaneous coronary intervention (PCI); heart failure requiring hospital readmission; or death from cardiovascular causes. STEMI patients were divided in 2 groups: “no MACE” ( $n = 38$ ) and “with MACE” ( $n = 12$ ).

Fasting blood samples were collected in EDTA-treated tubes upon admission to the hospital for SA and UA patients, while for STEMI patients, blood samples were collected upon discharge from the hospital, based on our previous study [22]. The highest levels of the measured parameters were determined at this time, compared to those at hospital admission or at the 6-month follow-up. None of the patients received heparin or fractionated heparin at the time of blood collection. Plasma was obtained by centrifugation at  $2000 \times g$  for 10' at 4 °C, aliquoted, and stored at  $-80$  °C until further processing.

The study was carried out in adherence to the principles of the Declaration of Helsinki (Code of Ethics of the World Medical Association, last updated at the 64th WMA General Assembly, Fortaleza, Brazil, October 2013) for experiments involving humans. All of the participants in the study gave their written informed consent by signing the respective paperwork and keeping their anonymity and privacy rights. The Ethics Committee of the Institute of Cellular Biology and Pathology “Nicolae Simionescu” (#1382/17, September 2012; #03/08, October 2019) approved the previous studies.

#### 4.2. Determination of Plasma Parameters of SA, UA, and STEMI Patients

The plasma parameters of the analyzed patients were measured using commercial kits. The TC, high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), and triglycerides kits were from Dialab (Neudorf, Austria); the ELISA kits for ApoA-I and ApoE were from Mabtech (Nacka Strand, Sweden); the ELISA kits for PON1, myeloperoxidase (MPO), and CRP were from R&D Systems (Minneapolis, MN, USA); and the enzymatic activity kit for lactate dehydrogenase (LDH) was from Biovision (Waltham, MA, USA). All assays were performed according to the manufacturers' instructions. PON1 enzymatic activity was measured using an adapted method in the plasma of the patients [2]. Glucose levels were measured by the hospital's laboratory.

#### 4.3. Analysis of ncRNAs in the Plasma of SA, UA, and STEMI Patients

Plasma ncRNAs were isolated using the miRNeasy Serum/Plasma kit (Qiagen, Hilden, Germany), following the manufacturer's instructions. Twenty-five fmoles of synthetic cel-miR-39 (Life Technologies, Carlsbad, CA, USA) was added to each sample as a spike-in to correct for sample-to-sample variation, as previously described [22,37].

The isolated RNA was reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Waltham, MA, USA). In order to reverse-transcribe both lncRNAs and miRNAs, we used random primers (supplied by the kit) as well as specific reverse-transcription primers for miR-142-3p and miR-155-5p on a Veriti 96-Well Fast Thermal Cycler (Applied Biosystems, USA).

Because of the known low abundance of lncRNAs in circulation, a preamplification step was needed before the quantification of LIPCAR and MALAT1 levels by qPCR. This was performed using SsoAdvanced PreAmp Supermix (Bio-Rad Laboratories, Hercules, CA, USA), according to the manufacturer's instructions, on a Veriti 96-Well Fast Thermal Cycler (Applied Biosystems, USA).

Plasma expression levels of MALAT1 (00273907\_s1), hsa-miR-142-3p (ID 000464), and hsa-miR-155-5p (ID 002623) were measured using the TaqMan assay method (Thermo

Scientific, Waltham, MA, USA) according to the manufacturer's instructions. This method included: a hold stage at 50 °C for 2 min; 95 °C for 10 min; 45 cycles of 95 °C for 10 s then 62 °C for lncRNAs or 60 °C for miRNAs for 1 min; followed by fluorescence readings using the ViiA7 Real-Time PCR System (Applied Biosystems, USA). For LIPCAR, we used custom primers and a custom-designed probe (See Table S9, Supplementary Material for detailed sequences). The expression level of each individual ncRNA was determined relative to that of exogenously added cel-miR-39 (ID 000200) and calculated using the  $2^{-\Delta Cq}$  method [35].

#### 4.4. Statistical Analysis

Statistical analysis and graphical representations of the study's data were performed using SPSS software for Windows (IBM SPSS 26.0, IBM Ireland, Dublin, Ireland) and GraphPad Prism 9.0 (GraphPad Software Inc., San Diego, CA, USA). Correlation plots were designed using Statistical Software Package R 4.2.2 (particularly *xlsx* and *corrplot* packages) and R-studio for Windows (version 2022.12.0+353); scatter plots for correlations of ncRNAs with glucose levels were created using SPSS 26.0 Graph builder. To increase the power of the statistical analysis, we used log-transformed data for lncRNA and miRNA levels. The continuous distributed quantitative variables (age, biochemical, lncRNA, and miRNA data) were expressed as mean  $\pm$  standard error of the mean (SEM) and analyzed using the independent Student's *t*-test for comparisons between study groups. To evaluate the differences between categorical variables (gender, presence of hyperglycemia, hypertension, hyperlipidemia, diabetes, and obesity), we used Crosstabs distribution with chi-squared ( $\chi^2$ ) analysis with Mantel–Haenszel common odds ratio (OR) estimates, performed using SPSS. Pearson's parametric bivariate correlation analysis for plasma lncRNA and miRNA levels with age and biochemical parameters was performed using SPSS. To analyze the potential of plasma lncRNA and miRNA levels to discriminate vulnerable CAD patients, univariate and multivariate receiver operating characteristic (ROC) analysis (2-value) was performed, adjusted for age and gender (females as reference group), considering the SA group as the reference category and the UA group as the risk (vulnerable) category. Similarly, univariate and multivariate ROC analysis was used to estimate the prediction potential for subsequent MACE in STEMI patients, using plasma lncRNA and miRNA levels and considering the "no MACE" group as the reference category and the "with MACE" group as the risk (vulnerable) category, adjusting for age and gender (females as reference group). The threshold for statistical significance was considered as 5% (*p*-values lower than 0.05).

**Supplementary Materials:** The supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijms241512076/s1>.

**Author Contributions:** Conceptualization, T.B., L.S.N., and A.V.S.; methodology, T.B., L.S.N. and F.P.; formal analysis, T.B. and L.S.N.; investigation, T.B; resources, T.B., C.S.S. and L.S.N.; data curation, T.B. and L.S.N.; writing—original draft preparation, T.B. and L.S.N.; writing—review and editing, C.S.S., F.P. and A.V.S.; visualization, T.B. and L.S.N.; supervision, L.S.N. and A.V.S.; funding acquisition, C.S.S. and L.S.N. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by a grant of the Romanian Ministry of Education and Research, CCCDI-UEFISCDI, project number PN-III-P2-2.1-PED-2019-1897, within PNCDI III. FP has received support from the French Government, managed by the National Research Agency (ANR) under the program "Investissements d'avenir", reference number ANR-16-RHUS-0003. FP is a member of FHU-CARNAVAL. This manuscript is based upon work from EU-CardioRNA COST Action CA17129 ([www.cardiorna.eu](http://www.cardiorna.eu)) supported by COST (European Cooperation in Science and Technology). TB received a "Short-Term Scientific Mission" grant awarded by EU-CardioRNA COST Action CA17129.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Institute of Cellular Biology and Pathology "Nicolae Simionescu" (#1382/17, September 2012; #03/08, October 2019).

**Informed Consent Statement:** Written informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Acknowledgments:** The authors thank Daniela Rogoz and Cristina Dobre (Lipidomics Department) for their skillful technical assistance.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Knuuti, J.; Wijns, W.; Saraste, A.; Capodanno, D.; Barbato, E.; Funck-Brentano, C.; Prescott, E.; Storey, R.F.; Deaton, C.; Cuisset, T.; et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur. Heart J.* **2020**, *41*, 407–477. [[CrossRef](#)] [[PubMed](#)]
2. Carnuta, M.G.; Stancu, C.S.; Toma, L.; Sanda, G.M.; Niculescu, L.S.; Deleanu, M.; Popescu, A.C.; Popescu, M.R.; Vlad, A.; Dimulescu, D.R.; et al. Dysfunctional high-density lipoproteins have distinct composition, diminished anti-inflammatory potential and discriminate acute coronary syndrome from stable coronary artery disease patients. *Sci. Rep.* **2017**, *7*, 7295. [[CrossRef](#)]
3. Huarte, M.; Rinn, J.L. Large non-coding RNAs: Missing links in cancer? *Hum. Mol. Genet.* **2010**, *19*, R152–R161. [[CrossRef](#)] [[PubMed](#)]
4. Holdt, L.M.; Beutner, F.; Scholz, M.; Gielen, S.; Gabel, G.; Bergert, H.; Schuler, G.; Thiery, J.; Teupser, D. ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. *Arterioscler. Thromb. Vasc. Biol.* **2010**, *30*, 620–627. [[CrossRef](#)]
5. Cakmak, H.A.; Demir, M. MicroRNA and Cardiovascular Diseases. *Balkan Med. J.* **2020**, *37*, 60–71. [[CrossRef](#)]
6. Islas, J.F.; Moreno-Cuevas, J.E. A MicroRNA Perspective on Cardiovascular Development and Diseases: An Update. *Int. J. Mol. Sci.* **2018**, *19*, 2075. [[CrossRef](#)]
7. Colpaert, R.M.W.; Calore, M. MicroRNAs in Cardiac Diseases. *Cells* **2019**, *8*, 737. [[CrossRef](#)]
8. Bhat, S.A.; Ahmad, S.M.; Mumtaz, P.T.; Malik, A.A.; Dar, M.A.; Urwat, U.; Shah, R.A.; Ganai, N.A. Long non-coding RNAs: Mechanism of action and functional utility. *Noncoding RNA Res.* **2016**, *1*, 43–50. [[CrossRef](#)]
9. Noh, J.H.; Kim, K.M.; McClusky, W.G.; Abdelmohsen, K.; Gorospe, M. Cytoplasmic functions of long noncoding RNAs. *Wiley Interdiscip. Rev. RNA* **2018**, *9*, e1471. [[CrossRef](#)]
10. Paraskevopoulou, M.D.; Hatzigeorgiou, A.G. Analyzing MiRNA-LncRNA Interactions. *Methods Mol. Biol.* **2016**, *1402*, 271–286. [[CrossRef](#)] [[PubMed](#)]
11. Johnsson, P.; Lipovich, L.; Grander, D.; Morris, K.V. Evolutionary conservation of long non-coding RNAs; sequence, structure, function. *Biochim. Biophys. Acta* **2014**, *1840*, 1063–1071. [[CrossRef](#)] [[PubMed](#)]
12. Dorn, G.W., 2nd. LIPCAR: A mitochondrial lnc in the noncoding RNA chain? *Circ. Res.* **2014**, *114*, 1548–1550. [[CrossRef](#)] [[PubMed](#)]
13. Kumarswamy, R.; Bauters, C.; Volkman, I.; Maury, F.; Fetsch, J.; Holzmann, A.; Lemesle, G.; de Groote, P.; Pinet, F.; Thum, T. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. *Circ. Res.* **2014**, *114*, 1569–1575. [[CrossRef](#)] [[PubMed](#)]
14. Yan, L.; Zhang, Y.; Wang, M.; Wang, L.; Zhang, W.; Ge, Z.R. Circulating LIPCAR is a potential biomarker of heart failure in patients post-acute myocardial infarction. *Exp. Biol. Med.* **2021**, *246*, 2589–2594. [[CrossRef](#)]
15. Hu, N.; Zeng, X.; Tang, F.; Xiong, S. Exosomal long non-coding RNA LIPCAR derived from oxLDL-treated THP-1 cells regulates the proliferation of human umbilical vein endothelial cells and human vascular smooth muscle cells. *Biochem. Biophys. Res. Commun.* **2021**, *575*, 65–72. [[CrossRef](#)]
16. Wang, X.; Li, D.; Chen, H.; Wei, X.; Xu, X. Expression of Long Noncoding RNA LIPCAR Promotes Cell Proliferation, Cell Migration, and Change in Phenotype of Vascular Smooth Muscle Cells. *Med. Sci. Monit.* **2019**, *25*, 7645–7651. [[CrossRef](#)]
17. Zhang, X.; Hamblin, M.H.; Yin, K.J. The long noncoding RNA Malat1: Its physiological and pathophysiological functions. *RNA Biol.* **2017**, *14*, 1705–1714. [[CrossRef](#)]
18. Yan, Y.; Song, D.; Song, X.; Song, C. The role of lncRNA MALAT1 in cardiovascular disease. *IUBMB Life* **2020**, *72*, 334–342. [[CrossRef](#)]
19. Huangfu, N.; Xu, Z.; Zheng, W.; Wang, Y.; Cheng, J.; Chen, X. LncRNA MALAT1 regulates oxLDL-induced CD36 expression via activating beta-catenin. *Biochem. Biophys. Res. Commun.* **2018**, *495*, 2111–2117. [[CrossRef](#)]
20. Huang, C.; Han, J.; Wu, Y.; Li, S.; Wang, Q.; Lin, W.; Zhu, J. Exosomal MALAT1 derived from oxidized low-density lipoprotein-treated endothelial cells promotes M2 macrophage polarization. *Mol. Med. Rep.* **2018**, *18*, 509–515. [[CrossRef](#)]
21. Zheng, B.; Yin, W.N.; Suzuki, T.; Zhang, X.H.; Zhang, Y.; Song, L.L.; Jin, L.S.; Zhan, H.; Zhang, H.; Li, J.S.; et al. Exosome-Mediated miR-155 Transfer from Smooth Muscle Cells to Endothelial Cells Induces Endothelial Injury and Promotes Atherosclerosis. *Mol. Ther.* **2017**, *25*, 1279–1294. [[CrossRef](#)] [[PubMed](#)]
22. Barbalata, T.; Scarlatescu, A.I.; Sanda, G.M.; Toma, L.; Stancu, C.S.; Dorobantu, M.; Micheu, M.M.; Sima, A.V.; Niculescu, L.S. Mitochondrial DNA Together with miR-142-3p in Plasma Can Predict Unfavorable Outcomes in Patients after Acute Myocardial Infarction. *Int. J. Mol. Sci.* **2022**, *23*, 9947. [[CrossRef](#)] [[PubMed](#)]
23. Chen, L.; Hu, L.; Zhu, X.; Wang, Y.; Li, Q.; Ma, J.; Li, H. MALAT1 overexpression attenuates AS by inhibiting ox-LDL-stimulated dendritic cell maturation via miR-155-5p/NFIA axis. *Cell Cycle* **2020**, *19*, 2472–2485. [[CrossRef](#)] [[PubMed](#)]

24. Yu, Q.; Xiang, L.; Chen, Z.; Liu, X.; Ou, H.; Zhou, J.; Yang, D. MALAT1 functions as a competing endogenous RNA to regulate SMAD5 expression by acting as a sponge for miR-142-3p in hepatocellular carcinoma. *Cell Biosci.* **2019**, *9*, 39. [[CrossRef](#)] [[PubMed](#)]
25. Zhang, Z.; Gao, W.; Long, Q.Q.; Zhang, J.; Li, Y.F.; Liu, D.C.; Yan, J.J.; Yang, Z.J.; Wang, L.S. Increased plasma levels of lncRNA H19 and LIPCAR are associated with increased risk of coronary artery disease in a Chinese population. *Sci. Rep.* **2017**, *7*, 7491. [[CrossRef](#)] [[PubMed](#)]
26. de Gonzalo-Calvo, D.; Kenneweg, F.; Bang, C.; Toro, R.; van der Meer, R.W.; Rijzewijk, L.J.; Smit, J.W.; Lamb, H.J.; Llorente-Cortes, V.; Thum, T. Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes. *Sci. Rep.* **2016**, *6*, 37354. [[CrossRef](#)]
27. Li, M.; Wang, Y.F.; Yang, X.C.; Xu, L.; Li, W.M.; Xia, K.; Zhang, D.P.; Wu, R.N.; Gan, T. Circulating Long Noncoding RNA LIPCAR Acts as a Novel Biomarker in Patients with ST-Segment Elevation Myocardial Infarction. *Med. Sci. Monit.* **2018**, *24*, 5064–5070. [[CrossRef](#)]
28. Li, R.; Jin, J.; Liu, E.; Zhang, J. A novel circulating biomarker lnc-MALAT1 for acute myocardial infarction: Its relationship with disease risk, features, cytokines, and major adverse cardiovascular events. *J. Clin. Lab. Anal.* **2022**, *36*, e24771. [[CrossRef](#)]
29. Vausort, M.; Wagner, D.R.; Devaux, Y. Long noncoding RNAs in patients with acute myocardial infarction. *Circ. Res.* **2014**, *115*, 668–677. [[CrossRef](#)]
30. Lv, F.; Liu, L.; Feng, Q.; Yang, X. Long non-coding RNA MALAT1 and its target microRNA-125b associate with disease risk, severity, and major adverse cardiovascular event of coronary heart disease. *J. Clin. Lab. Anal.* **2021**, *35*, e23593. [[CrossRef](#)]
31. Kong, X.; Wang, J.; Cao, Y.; Zhang, H.; Lu, X.; Wang, Y.; Bo, C.; Wang, T.; Li, S.; Tian, K.; et al. The long noncoding RNA MALAT-1 functions as a competing endogenous RNA to regulate MSL2 expression by sponging miR-338-3p in myasthenia gravis. *J. Cell. Biochem.* **2019**, *120*, 5542–5550. [[CrossRef](#)] [[PubMed](#)]
32. Polisenio, L.; Salmena, L.; Zhang, J.; Carver, B.; Haveman, W.J.; Pandolfi, P.P. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. *Nature* **2010**, *465*, 1033–1038. [[CrossRef](#)] [[PubMed](#)]
33. Wang, Q.; Lu, G.; Chen, Z. MALAT1 promoted cell proliferation and migration via MALAT1/miR-155/MEF2A pathway in hypoxia of cardiac stem cells. *J. Cell. Biochem.* **2019**, *120*, 6384–6394. [[CrossRef](#)] [[PubMed](#)]
34. Chen, M.X.; Chen, L.D.; Huang, J.C.; Zeng, A.M.; Huang, J.F.; Lin, Q.C. Long non-coding RNA MALAT1 affects intermittent hypoxia-induced endothelial injury by regulating miR-142-3p/HMGB1. *Sleep Breath.* **2022**, *26*, 2015–2024. [[CrossRef](#)] [[PubMed](#)]
35. Niculescu, L.S.; Simionescu, N.; Sanda, G.M.; Carnuta, M.G.; Stancu, C.S.; Popescu, A.C.; Popescu, M.R.; Vlad, A.; Dimulescu, D.R.; Simionescu, M.; et al. MiR-486 and miR-92a Identified in Circulating HDL Discriminate between Stable and Vulnerable Coronary Artery Disease Patients. *PLoS ONE* **2015**, *10*, e0140958. [[CrossRef](#)] [[PubMed](#)]
36. Collet, J.P.; Thiele, H.; Barbato, E.; Barthelémy, O.; Bauersachs, J.; Bhatt, D.L.; Dendale, P.; Dorobantu, M.; Edvardsen, T.; Folliguet, T.; et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur. Heart J.* **2021**, *42*, 1289–1367. [[CrossRef](#)] [[PubMed](#)]
37. Barbalata, T.; Moraru, O.E.; Stancu, C.S.; Devaux, Y.; Simionescu, M.; Sima, A.V.; Niculescu, L.S. Increased miR-142 Levels in Plasma and Atherosclerotic Plaques from Peripheral Artery Disease Patients with Post-Surgery Cardiovascular Events. *Int. J. Mol. Sci.* **2020**, *21*, 9600. [[CrossRef](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.